Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...
The Pharma Specialized Network (PSN) provides a globally integrated solution for delivering end-to-end distribution to ...
The evolving role of early-phase clinical trials reflects a broader truth: decisions made early carry increasing weight in ...
To understand the key trends and client conversations that shaped this year's summit, pharmaphorum sat down with Krista Pinto ...
Across events and general day-to-day industry updates, one term has dominated market access conversations in 2026: Most ...
Italy's Angelini Pharma has agreed to buy Catalyst Pharma of the US for up to $4.1 billion, saying the deal is a "pivotal moment" in its 100-year-plus history. Privately held Angelini will pay $31.50 ...
EVERSANA has named Mike Guarino to lead its global health agency EVERSANA INTOUCH, which was formed in 2022 by the merger of ...
Radiotracer-enhanced PET/CT scan, showing positive uptake in the heart of patient with cardiac amyloidosis. Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging ...
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US regulator ...
The final ICH E6 (R3) Good Clinical Practice (GCP) Guidelines were published on 6 th January 2025, updating the framework for clinical trials to reflect modern trial designs, technology, and data ...
Novartis has signed its second licensing deal with Monte Rosa Therapeutics in less than a year, suggesting it is impressed with the US biotech's molecular glue degrader (MGD) platform. The latest ...
Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results